The ban on “pay to delay” pharma patent settlements: shaving health care costs, fighting anti-competition, and patents — all rolled up into one


2 July 2010 – The U.S. House of Representatives has passed a measure banning patent settlements struck between brand-name and generic pharmaceutical companies to delay the release of generic drugs. The goal? To shave nearly $2 billion off government spending over the next decade. The measure was tacked onto the Iraq and Afghanistan war funding bill.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.